TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06569797

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oligosaccharides and multiple nutrients
Description: The effect of adding milk oligosaccharides and optimizing multiple nutrients to infant formula on the growth and development of infants aged 0-1 years

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: no oligosaccharides and optimizing multiple nutrients
Description: The effect of traditional infant formula milk powder optimized without adding milk oligosaccharides and multiple nutrients on the growth and development of infants aged 0-1 years old.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: breastfeeding
Description: The impact of breastfeeding on the growth and development of infants aged 0-1 years old.
Study: NCT05906589

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: The participant will take inulin twice daily over a 14 day period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: The participant will take inulin twice daily over a 14 day period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium
Description: The participant will take psyllium twice daily over a 14 day period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: The participant will take maltodextrin twice daily over a 14 day period.
Study: NCT06577870

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hospitalization in intensive care or continuing care unit
Description: Hospitalization in intensive care or continuing care unit for medical reasons or surgery, conscious or unconscious under mechanical ventilation. Resuscitation patients are then cared for in a continuing care unit.
Study: NCT05398848

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant two-component COVID-19 vaccine (CHO cell)
Description: Before reconstitution: Lyophilized powder for reconstitution in single-use vials After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Before reconstitution:~Lyophilized powder for reconstitution in single-use vials~After reconstitution with BFA03 adjuvant:~Milk-white solution with no visible foreign matter
Study: NCT05468177

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy
Description: Cetuximab: 500mg/m2,day1, every 2 weeks. mFOLFOX: oxaliplatin 85mg/m2, day 1;LV 400mg/m2, day 1;5-FU 400mg/m2, day 1, then 1200mg/ (m2•d) ×2days(total 2400mg/m2, infusion 46-48h) (every 2 weeks).~Anti-PD-1(Sintilimab Injection):200mg every 3 weeks. Surgery will be performed after 4 cycles for locally advanced or initially resectable metastatic right colon cancer.If the initial unresectable metastatic right colon cancer were converted into resectable metastases, and surgery will be performed. Patients who failed to convert after 6 cycles of treatment will be withdrawn from the study.Cetuximab +mFOLFOX was treat for 8 cycles, and Anti-PD-1 was treated for one year in the perioperation period unless disease progression, toxicity intolerance, initiation of new anti-tumor therapy.
Study: NCT06261060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given by PO
Study: NCT04743856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ActiveGOALSv2
Description: 13 weekly self-guided sessions on problem solving and goal setting related to increasing physical activity, and weekly remote coaching support. Once a month support materials sent monthly from months 4-12 of intervention.
Study: NCT04781972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: single dose of 10 mg or 15 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: single dose of 10 mg or 15 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT05050279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib capsule
Description: oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib capsule
Description: oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib capsule
Description: oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib capsule
Description: oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: oral capsule
Study: NCT06577870

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hospitalization in intensive care or continuing care unit
Description: Hospitalization in intensive care or continuing care unit for medical reasons or surgery, conscious or unconscious under mechanical ventilation. Resuscitation patients are then cared for in a continuing care unit.
Study: NCT06409286

Intervention type: DEVICE
Intervention: Thermal Anisotropy Measurement Device
Description: A wireless device for non-invasively assessing CSF shunt flow
Study: NCT04578041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRPMS (Transcranial Rotating Permanent Magnet Stimulation)
Description: TRPMS ( is administered through a head cap worn by the participant and controlled by QHTimeStimulate application via computer tablet.~* Modality: Excitatory stimulation~* Frequency: 5 Hz~* Interval between stimulus: 100 ms~* Duration of each stimulus: 25 ms~* Duration of stimulation: 40 minutes~* Position of microstimulators: over primary motor cortex and supplementary motor area for Arm 1; over left and right dorsolateral prefrontal cortex for Arm 2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRPMS (Transcranial Rotating Permanent Magnet Stimulation)
Description: TRPMS ( is administered through a head cap worn by the participant and controlled by QHTimeStimulate application via computer tablet.~* Modality: Excitatory stimulation~* Frequency: 5 Hz~* Interval between stimulus: 100 ms~* Duration of each stimulus: 25 ms~* Duration of stimulation: 40 minutes~* Position of microstimulators: over primary motor cortex and supplementary motor area for Arm 1; over left and right dorsolateral prefrontal cortex for Arm 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Program
Description: Aerobic exercise consisting of 40 minutes of cycling training with a seated elliptical machine. The daily physical activity program will consist of three 10-minute bouts of aerobic exercise interspersed with two 5-minute bouts of rest. The participants will exercise maintaining their Heart Rate (HR) at least between 60-80% of the maximum age-related HR.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computerized CT (Cognitive Training)
Description: Computerized cognitive training (CT) consisting of 40 minutes Brain-HQ training.~The adaptive cognitive training games also serve to engage them during the stimulation session, and to keep them seated at the computer for the entire duration of the session.
Study: NCT06502028

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video laryngeal mask airway
Description: The airway is secured with a video laryngeal mask airway.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube
Description: The participant is intubated with an endotracheal tube via direct laryngoscopy.
Study: NCT05559385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-Assissted Therapy
Description: Houston Bionics ExoRehab X brand/model device was used for improving the upper extremity in subacute stroke.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: It is an upper extremity rehabilitation program prepared in line with individual needs.
Study: NCT05510167

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Study arm
Description: Participants will be asked to completely abstain from drinking or consume 2 or less drinks per week for 8 months following catheter ablation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Study arm
Description: Participants will be asked to completely abstain from drinking or consume 2 or less drinks per week for 8 months following catheter ablation
Study: NCT06008301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: State-Trait Anxiety Inventory (STAI)
Description: The State-Trait Anxiety Inventory (STAI) has 20 items for assessing trait anxiety and 20 for state anxiety.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: State-Trait Anxiety Inventory (STAI)
Description: The State-Trait Anxiety Inventory (STAI) has 20 items for assessing trait anxiety and 20 for state anxiety.
Study: NCT06462586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone
Description: Lumateperone 42 mg capsules administered orally, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsules administered orally, once daily
Study: NCT04743856

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PAT
Description: Participants will receive a physical activity tracker and encouragement to increase activity.
Study: NCT04908449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rectus sheath block with bupivacaine
Description: Rectus sheath block with local anesthetic versus sham block with saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rectus sheath block with bupivacaine
Description: Rectus sheath block with local anesthetic versus sham block with saline
Study: NCT05091112

Intervention type: PROCEDURE
Intervention: Spinal surgery
Description: In participants who undergo elective lumbar spinal surgery and consented for research, the medial branch and dorsal rami will be harvested for histological analysis.

Intervention type: OTHER
Intervention: Histology
Description: The harvested nerves will be fixed, cut into smaller sections. Analysis of macroscopic and light microscopic sections will be carried out
Study: NCT06079476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Single-use prefilled syringe for SC injection.
Study: NCT05047913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FTX
Description: Given By IV
Study: NCT06168019

Intervention type: OTHER
Intervention: Exposures
Description: COVID-19, Influenza and ORV impact on the pregnant woman, her fetus and newborn
Study: NCT06652529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AROG4-01
Description: AROG4-01 will be administered as IV infusions in biweekly dosing interval. The first dosing day will be Day 1, 28 days cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AROG4-01
Description: AROG4-01 will be administered as IV infusions in biweekly dosing interval. The first dosing day will be Day 1, 28 days cycle.~This study is an open label, Phase 1 dose escalation trial with two expansion cohorts. The study consists of two parts:~* Part A: Dose escalation in patients with advanced solid tumors. Approximately 8 to 20 patients in total will be enrolled in part A, covering up to 6 dose levels.~* Part B: At the dose expansion phase, AROG4-01 two cohorts of ten patients with advanced solid tumor each will be recruited. One cohort of patients with advanced MPM (cohort 1) and a second cohort of patients with other solid tumors (cohort 2).
Study: NCT06670365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat acclimation by warm-water immersion
Description: Participants will be immersed in a whirlpool tub to the shoulder level in a circulated water bath maintained at \~40°C until their core temperature achieves a steady-state of 38.5°C for 60 minutes. The warm-water immersion protocol will be repeated for 6 more consecutive days.
Study: NCT06597916

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arexvy powder and suspension for injection
Description: Arexvy powder and suspension for injection (RSV vaccine)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Arexvy powder and suspension for injection
Description: Arexvy powder and suspension for injection (RSV vaccine)
Study: NCT06617026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucralfate
Description: a topical rectal ointment. The patients are instructed to apply it twice a day, using a gloved finger, inside the anal canal and the perianal region for 40 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azadirachtin
Description: a topical oil. The patients are instructed to apply it twice a day, using a gloved finger, inside the anal canal and the perianal region for 40 days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fissurectomy and lateral sphincterectomy
Description: fissurectomy and lateral sphincterectomy
Study: NCT06681883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action group
Description: A nursing care program based on the Model of Modifiable Factors Specific to Problematic Internet Use in Adolescents (MFPA)~The nursing care program based on the MFPA model is designed for adolescents with problematic internet use. The program is grounded in the concepts of the draft model. It consists of eight sessions, each expected to last 40-50 minutes. One session will be held per week. The first session includes introductions and an overview of the program, the second session aims to strengthen the adolescent's motivation for change, the third session focuses on improving the adolescent's self-control skills, the fourth session aims to enhance family functionality, the fifth session helps develop offline activities to replace internet use, the sixth and seventh sessions work on developing coping skills, and the eighth session includes the evaluation and termination of the program.
Study: NCT06681168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous auricular vagal nerve stimulation
Description: Participants will be randomly assigned to receive either taVNS applied to the tragus of the ear or a sham stimulation from the time of randomization for 90 days.~Active simulations will be carried out daily using the Parasym device for 60 minutes twice daily during the acute phase (two sessions, one in the morning and one in the afternoon), and once daily (single session) during the rehabilitation phase. The stimulation waveform includes trains of pulses with widths of 200 µs and repetition rate of 20 Hz (Nurosym proprietary waveform); current delivery will be set at a predefined therapeutic level below 0.25 W/cm² (Watts per centimeter squared), that being the defined risk threshold for a thermal burn. The device adjusts stimulation intensity at 0.8 mA steps; the starting intensity will be set at 16 mA (level 20).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: The sham stimulation involves placing the electrode on the same site without delivering any electrical current. The device will be applied to the tragus without electrical current delivered from the time of randomization for 90 days (i.e., the time of randomization coincides with the first stimulation session).
Study: NCT05024773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)
Description: Schedule: once a week for 12 consecutive weeks (induction phase). Patients who achieve a complete response at the end of the induction phase will enter the maintenance phase, during which ONCOFID-P-B is administered once a month for 12 months until recurrence or progression of the disease.
Study: NCT05730699

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: divozilimab
Description: anti-CD20 monoclonal antibody
Study: NCT06595121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: Budesonide 1 mg/2mL nebuliser suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: Budesonide 1 mg/2mL nebuliser suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Description: Pulmicort(r) 1 mg/2mL nebuliser suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Description: Pulmicort(r) 1 mg/2mL nebuliser suspension
Study: NCT06306274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus (0,1%) ointment
Study: NCT06595121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activated Charcoal
Description: suspension of 10g activated charcoal slurried in 70mL of water
Study: NCT06680635

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavonoid-enriched juice and a low-calorie diet
Description: Orange juice enriched in flavonoids (14%: nobiletin, sinensetin, tangeretin) (200 ml/day) and low calorie diet
Study: NCT05314387

Intervention type: DEVICE
Intervention: SMR TT Hybrid Glenoid without Cementless Finned Short Stem
Description: The subject SMR Hybrid Glenoid System and SMR cementless finned short stem is intended for both primary or revision anatomic and reverse shoulder joint replacement. The glenoid components when used as part of an anatomic shoulder replacement are intended for cemented fixation.

Intervention type: DEVICE
Intervention: SMR TT Hybrid Glenoid with Cementless Finned Short Stem
Description: The subject SMR Hybrid Glenoid System and SMR cementless finned short stem is intended for both primary or revision anatomic and reverse shoulder joint replacement. The glenoid components when used as part of an anatomic shoulder replacement are intended for cemented fixation.~The fins are intended to enhance press-fit fixation. The same proximal morse taper is used for coupling to the same humeral bodies in the SMR Shoulder System. The SMR finned short stem is intended for cementless fixation.
Study: NCT06306274

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ointment
Study: NCT06680635

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Food supplement: placebo juice and a low calorie diet
Description: Placebo juice (200 ml/day) and a low calorie diet
Study: NCT06681038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: Intravenous doublet chemotherapy FOLFIRI or FOLFIRINOX + targeted systemic therapy (anti-EGFR or anti-VEGF).~Administered every 2 weeks for 12 cycles. Dosage and administration at recommended doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy
Description: Intravenous doublet chemotherapy FOLFIRI or FOLFIRINOX + targeted systemic therapy (anti-EGFR or anti-VEGF).~Administered every 2 weeks for 12 cycles. Dosage and administration at recommended doses.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PIPAC
Description: In addition to standard systemic treatment, patients receive also four PIPAC procedures with pressurized aerosol containing oxaliplatin.~The PIPAC procedure is repeated up to a maximum of 4 times every 6 weeks.
Study: NCT06680700

Intervention type: DEVICE
Intervention: Perin Health Patch
Description: The Perin Health Patch (PHP) is a non-invasive, chest-worn device designed to monitor blood oxygen saturation (SpO2) and additional vital signs, including heart rate, respiratory rate, ECG, and bioimpedance (BioZ). Unlike traditional fingertip pulse oximeters, the PHP integrates multi-wavelength photoplethysmography (PPG) sensors with ECG and BioZ technology, allowing for continuous SpO2 tracking even during movement and daily activities.
Study: NCT06681285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab ;Anlotinib
Description: Cadonilimab Combined With Anlotinib Followed by Radiotherapy in the Second and Later-line Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Study: NCT06681311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: During the research period, all participants will undergo swimming training for 1 hour per day, 3-4 days a week for 6 weeks. The control group will perform a 5-minute land warm-up covering traditional shoulder, torso, and leg areas before their routine swimming training. In addition to the traditional warm-up program and swimming training, the experimental group will also participate in core and shoulder stabilization exercises under the supervision of a physiotherapist.
Study: NCT06680388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug：CD19 CAR-T
Description: A total of 3 dose groups were set, with dose group 1 as the starting dose, which was performed according to the traditional 3 + 3 design rule as a single intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug：CD19 CAR-T
Description: A total of 3 dose groups were set, with dose group 1 as the starting dose, which was performed according to the traditional 3 + 3 design rule as a single intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug：CD19 CAR-T
Description: A total of 3 dose groups were set, with dose group 1 as the starting dose, which was performed according to the traditional 3 + 3 design rule as a single intravenous infusion.
Study: NCT06154525

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: RO water
Description: Aquafina's reverse osmosis (RO) water, produced by PepsiCo, have both obtained ISO 9001:2015 and ISO 22000:2018 certifications, which are internationally recognized standards for quality management and food safety management systems, respectively. The RO water ampoules are produced using a similar process as the LIVESPO Preg-Mom/ KIDS but contain 5ml of high-quality RO water from Aquafina (proper noun)
Study: NCT06680388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug：CD19 CAR-T
Description: A total of 3 dose groups were set, with dose group 1 as the starting dose, which was performed according to the traditional 3 + 3 design rule as a single intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug：CD19 CAR-T
Description: A total of 3 dose groups were set, with dose group 1 as the starting dose, which was performed according to the traditional 3 + 3 design rule as a single intravenous infusion.
Study: NCT06117397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Messaging Intervention
Description: A text messaging intervention that includes enhanced content such as tailoring, video links and a chat function
Study: NCT06154525

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LiveSpo Preg-Mom
Description: LiveSpo® Preg-Mom has a registration number 7695/2020/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LiveSpo KIDS
Description: LiveSpo® KIDS has a registration number 1537/2023/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam.